SOURCE: StockCall

StockCall

June 20, 2012 08:15 ET

Research on Valeant Pharmaceuticals International Inc. and Elan Corp. plc - Drug Delivery Companies Looking Strong

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jun 20, 2012) - www.StockCall.com offers free research on Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Elan Corp. plc (NYSE: ELN) from the Drug Delivery industry. Access these reports by clicking on the links below or by copy and pasting those to your address bar.

www.StockCall.com/reports

Companies in the drug delivery industry such as Valeant Pharmaceuticals International Inc. and Elan Corp. Plc. could be well positioned for growth. The ageing population in the developed world and the fast growing middle-classes in emerging markets promise to boost demand and provide ample room for expansion.

StockCall.com is an online platform where investors doing their due-diligence on the Drug Delivery industry can have easy and free access to our analyst research and opinions on Valeant Pharmaceuticals International Inc. and Elan Corp. plc. To see how companies in this industry have grown over the past years and how they are expected to perform in the future, please visit the link below.

www.StockCall.com

Canadian drug maker Valeant Pharmaceuticals has been on something of an acquisition spree recently, expanding its offerings as well as its global reach. The company has acquired a number of global assets of late, and most recently it has announced plans to buy specialty oral health products company OraPharma from Water Street Healthcare Partners for around $312 million. Also expected to close this month is the company's acquisition of certain assets from Swiss Herbal Remedies Limited. Investors and shareholders of Valeant Pharmaceuticals International Inc. can simply register for our complimentary report by clicking on the link below.

www.StockCall.com/VRX200612.pdf

Elsewhere in the industry, Elan Corp. recently announced that in a joint project with Biogen Idec it has developed a risk stratification algorithm to help MS patients to better comprehend and evaluate their particular risks and benefits potential when considering using TYSABRI as a treatment for relapsing forms of the illness. Register now to have free access to our report on Elan Corp. plc, and to do so please click the link below.

www.StockCall.com/ELN200612.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information